Safety of the trivalent, cold-adapted influenza vaccine (CAIV-T) in children

Seminars in Pediatric Infectious Diseases

Volumn 13, Issue 2, 2002, Pages 90-96

  Piedra, Pedro A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; NOSE SPRAY;

ABDOMINAL PAIN; ACUTE RESPIRATORY TRACT DISEASE; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEALTH CARE ORGANIZATION; HEALTH CARE UTILIZATION; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; LICENSING; PUBLICATION; REVIEW; SYMPTOMATOLOGY; VOMITING;

EID: 0036244710     PISSN: 10451870     EISSN: None     Source Type: Journal    
DOI: 10.1053/spid.2002.122995     Document Type: Article

References (65)

1. Burden of disease-implications for future research
2. Influenza in children. Relationship to other respiratory agents
3. The impact of winter epidemics of influenza and respiratory syncytial virus on paediatric admissions to an urban general hospital
4. Bronchiolitis-associated hospitalizations among US children, 1980-1996
5. Influenza and the rates of hospitalization for respiratory disease among inants and young children
6. The effects of influnza on hospitalization, outpatient visits, and courses of antiiotics in children
7. Acute respiratory disease associated with influenza epidemic in Houston, 1981-1983
8. Influenza: Its control in persons and populations
9. Influenza: Manifestations, treatment and prevention
10. Consideration of the risk of influenza in children and indications for prophylaxis
11. Severe pneumococal pneumonia in previously healthy children: The role of preceding influenza infection
12. PCR on cerebropinal fluid to show influenza-associated acute encephalopathy or encephalitis
13. Influenza B virus encephalitis
14. A study of acute respiratory disease in the community of Port Chalmers. II. Influenza A/Port Chalmrs/1/73: Intrafamilial spread and the effect of antibodies to the surface antigens
15. Influenzavirus infections in Seattle families, 1975-1979 I. Study design, methods, and the occurrence of infections by time and age
16. Influenza virus infecions in Seattle families, 1975-1979 II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness
17. Comparison of infection rates and severity of illness for influenza A subtypes H1N1 and H3N2
18. Influenza virus infecion in infants
19. Modification of an outbreak in Tecumseh, Michigan by vaccination of schoolchilren
20. New Modalities for preventing and treating influenza
21. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia
22. Emerging infections: Pandemic influenza
23. Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: Implications for influenza epidemic control
24. The Japanese experience with vaccinating schoolchildren against influenza
25. Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts
26. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza-virus vaccine in children
27. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine
28. Influenza A vaccine decreases the incidence of otitis media in 6- to 30-month-old children in day care
29. Influenza vaccination in the prevention of acute otitis media in children
30. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: The pediatric experience
31. Influenza in children, epidemiology, immunity, and vaccines
32. Live attenuated and inactivated influenza vaccine in school-aged children
33. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
34. The impact of influenza epidemics on mortality: Introducing a severity index
35. Pandemic versus epidemic influenza mortality: A pattern of changing age distribution
36. Potential cost savings attributable to influenza vaccination of school-aged children
37. Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children
38. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A(H1N1), A(H3N2), and B viruses
39. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults - A randomized controlled trial
40. Adaptation and growth characteristics of influenza virus at 25°C
41. Development and characterization of cold-adapted viruses for use as live virus vaccines
42. Four viral genes independently contribute to attenuation of live A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccine
43. A mutation in the PA protein gene of cold-adapted B/Ann Arbor/1/66 influenza virus associated with reversion of temperature sensitivity and attenuated virulence
44. Cold-adapted recombinant influenza A virus vaccines in seronegative young children
45. Cold-recombinant influenza A/California/10/78 (H1N1) virus vaccine (CR-37) in seronegative children: Infectivity and efficacy against investigational challenge
46. Live attenuated influenza A virus vaccines in children: Results of a field trial
47. Simultaneous administration of live attenuated influenza A vaccines representing different serotypes
48. Evaluation of cold-recombinant influenza A/Korea (CR-59) virus vaccines in infants
49. Evaluation of a cold-adapted influenza B/Texas/84 reassortant virus (CRB-87) vaccine in young children
50. Comparison of live attenuated cold-adapted and avian-human influenza A/Bethesda/85 (H3N2) reassortant virus vaccines in infants and children
51. The A/Mallard/6750/78 avian-human, but not the A/Ann Arbor/6/60 cold-adapted, influenza A/Kawasaki/86 (H1N1) reassortant virus vaccine retains partial virulence for infants and children
52. Safety and immunogenicity of live attenuated cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in infants and children
53. Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza type A (CRA) and inactivated trivalent influenza virus (TI) in infants and young children
54. Safety and immunogenicity of a cold-adapted influenza A (H1N1) reassortant virus vaccine administered to infants less than six months of age
55. Effective immunization with live attenuated influenza A virus can be achieved in early infancy
56. Evaluation of live attenuated influenza vaccines in children 6-18 months of age: Safety, immunogenicity, and efficacy
57. Immunization of infants and young children with live attenuated trivalent cold-recombinant influenza A H1N1, H3N2, and B vaccine
58. Multidose, live attenuated, cold-recombinant, trivalent influenza vaccine in infants and young children
59. Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children
60. Prospective, ranomized, placebo-controled evaluation of the safety and immuogenicity of three lots of intranasal trivalent influenza vaccine among children
61. Safety and effectiveness of the trivalent, cold-adapted influenza vaccine (CAIV-T) in children
62. Safety of the trivalent, cold-adapted influenza vaccine (CAIV-T) in pre-school aged children
63. Comparison of the clearance of radiolabelled nose drops and nasal spray as mucosally delivered vaccine
64. No increased risk for invasive bacterial infection found following diphtheria-tetanus-pertussis immunization
65. Multivariate cohort analysis